New China-US biotech gets $54M: Vivatides Therapeutics raised the Series A for its preclinical-stage R&D in siRNA and antisense oligonucleotides aimed at reaching tissues beyond the liver. Vivatides’ investors include …
More pharma dealmaking; FDA’s proposed budget; Takeda ends partnership; and more
Welcome back to another edition of Endpoints Weekly. Two of the year’s major oncology conferences are coming up soon: AACR starting April 17, and ASCO


